Market Introduction
miRNA is a small noncoding RNA molecule of 20-30 nucleotides and play an important role in gene regulation. miRNA is partially complementary to messenger RNA (mRNA) and its main function is to downregulate gene expression. Since their discovery they have emerged as vital regulators of important cellular functions. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis.
Market Overview and Dynamics
The Europe miRNA sequencing and assay market is expected to reach US$ 144.87 million by 2027 from US$ 62.30 million in 2019; it is estimated to grow at a CAGR of 11.3% from 2020 to 2027. The widening application range of microRNAs and rise in funding for genomics research. However, challenges associated with the delivery, efficacy, and specificity of miRNA-based therapeutics hinder the market growth.
MicroRNAs (miRNAs) being involved in the process of differentiation, they act as markers in cell type identification. miRNAs are associated with pathological processes such as viral infections, autoimmune diseases, and carcinogenesis. Thus, extensive research is being conducted to identify new miRNAs. Furthermore, new discoveries regarding the role of miRNAs in disease development have made them a key target of novel therapeutic approaches. Several miRNA-targeted therapeutics against the diseases such as cancer and hepatitis have reached the clinical phase. For instance, Santaris Pharma has developed a therapeutic molecule named Miravirsen that targets miR-122 for the treatment of hepatitis C virus (HCV) infection; the molecule is in the Phase II clinical trial. Therefore, rise in funding of genomic research to identify new molecules to diagnose and treat diseases, and consequent expansion of the range of applications of miRNAs are driving the growth of the miRNA sequencing and assay market in Europe.
The COVID-19 pandemic has been having some serious effects on European countries. The miRNA sequencing and assay market in the region witnessed shortfall at the beginning of the pandemic crisis due to disruptions in supply chain and lowered demands due to lockdown imposed by many European countries. However, later, the demand for the miRNA sequencing and assay products increased drastically with supportive government initiatives. Many private research organizations have expanded their research teams and projects to accelerate studies related to SARS-CoV-2. For instance, QIAGEN, Germany, a pioneer in next-generation sequencing (NGS), has expanded its integrated coronavirus next-generation sequencing platforms and software solutions to accelerate COVID-19 research. Hence, the COVID-19 pandemic has been supporting the Europe miRNA sequencing and assay market growth.
Key Market Segments
The Europe miRNA sequencing and assay market, by product, is segmented into library preparation and consumables. The consumables segment held a larger share of the market in 2019, whereas the library preparation segment is anticipated to register a higher CAGR in the market during the forecast period.
Based on technology, the Europe miRNA sequencing and assay market is segmented into sequencing by synthesis, nanopore, and ion semiconductor sequencing. The sequencing by synthesis segment held the largest share of the market in 2019; however, the nanopore segment is expected to register the highest CAGR in the market during 2020–2027.
Based on end user, the Europe miRNA sequencing and assay market is segmented into research institute, academia, and CROs. The research institute segment held the largest share of the market in 2019 and is estimated to register the highest CAGR in the market during the period.
Major Sources and Companies Listed
Some of the primary and secondary sources associated with this report on the Europe miRNA sequencing and assay market are the European Federation of Pharmaceutical Industries and Association (EFPIA), Spanish Society of Medical Oncology (SCOM) and Spanish Society of Pharmaceutics and Pharmaceutical Technology (SEFIG).
Reasons to buy the report
Europe MiRNA Sequencing and Assay Market Segmentation
By Product
By Technology
By End User
By Country
Company Profiles
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 62.30 Million |
| Market Size by 2027 | US$ 144.87 Million |
| CAGR (2020 - 2027) | 11.3% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe miRNA Sequencing and Assay Market is valued at US$ 62.30 Million in 2019, it is projected to reach US$ 144.87 Million by 2027.
As per our report Europe miRNA Sequencing and Assay Market, the market size is valued at US$ 62.30 Million in 2019, projecting it to reach US$ 144.87 Million by 2027. This translates to a CAGR of approximately 11.3% during the forecast period.
The Europe miRNA Sequencing and Assay Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe miRNA Sequencing and Assay Market report:
The Europe miRNA Sequencing and Assay Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe miRNA Sequencing and Assay Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe miRNA Sequencing and Assay Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe miRNA Sequencing and Assay Market
